objective responses (ORR)

mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive

versus sunitinib
atezolizumab alone vs. sunitinib 1 111 [-1526; 1748] /10000
15/54 vs. 16/60